Abstract | BACKGROUND: OBJECTIVE: METHODS: Subset analyses of a phase II, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis were performed. Improvement from baseline in Psoriasis Area and Severity Index score of 75%, 90%, and 100% at week 12; static Physician Global Assessment (0/1) score; Dermatology Life Quality Index response; and Psoriasis Symptom Inventory response were evaluated within subgroups. RESULTS: Efficacy and quality-of-life measures were generally similar between subgroups of patients with or without a history of PsA and with or without a history of biologic use across brodalumab doses and were significantly higher among patients who received brodalumab 140 mg every 2 weeks or 210 mg every 2 weeks versus placebo. LIMITATIONS: Differences between subgroups were not compared statistically, PsA was self-reported, only skin involvement/symptoms were reported, and reasons for discontinuation of prior biologic were not captured. CONCLUSION:
|
Authors | Kim Papp, Alan Menter, Bruce Strober, Greg Kricorian, Elizabeth H Z Thompson, Cassandra E Milmont, Ajay Nirula, Paul Klekotka |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 72
Issue 3
Pg. 436-439.e1
(Mar 2015)
ISSN: 1097-6787 [Electronic] United States |
PMID | 25553889
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- brodalumab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Arthritis, Psoriatic
(drug therapy)
- Double-Blind Method
- Humans
- Psoriasis
(drug therapy)
- Severity of Illness Index
|